Get the Stockscreener App
5.21
1.56%
0.08
After Hours:
5.31
0.10
+1.92%
Protara Therapeutics Inc stock is traded at $5.21, with a volume of 424.31K.
It is up +1.56% in the last 24 hours and down -0.95% over the past month.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
See More
Previous Close:
$5.13
Open:
$5.16
24h Volume:
424.31K
Relative Volume:
0.41
Market Cap:
$281.78M
Revenue:
-
Net Income/Loss:
$-57.44M
P/E Ratio:
-3.8994
EPS:
-1.3361
Net Cash Flow:
$-56.46M
1W Performance:
-0.19%
1M Performance:
-0.95%
6M Performance:
-8.92%
1Y Performance:
+24.94%
1-Day Range:
$5.105
$5.27
1-Week Range:
$4.92
$5.32
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.21 | 277.45M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | JP Morgan | Overweight |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara's experimental bladder cancer drug shows encouraging results - MSN
Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS
Published on: 2026-04-14 02:30:36 - baoquankhu1.vn
Exit Recap: Can Protara Therapeutics Inc beat the S P 5002026 Institutional & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Retail Trends: Can Protara Therapeutics Inc beat the S P 5002026 Institutional Moves & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Will Protara Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Sell: Jacqueline Zummo Sells Shares of Protara Therapeutics Inc (TARA) - GuruFocus
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock - Investing.com Canada
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) R&D chief sells 1,134 shares under 10b5-1 plan - Stock Titan
Quarterly Risk: Is Protara Therapeutics Inc trading at a discountBuy Signal & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Sentiment Review: Whats Protara Therapeutics Incs historical returnWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Investor Mood: Can Protara Therapeutics Inc deliver consistent EPS growth2026 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Th - GuruFocus
Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock - MarketBeat
Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan - Stock Titan
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Risk Hedge: What is the target price for Protara Therapeutics Inc stock2026 Trading Recap & Momentum Based Trading Ideas - baoquankhu1.vn
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results - TipRanks
Protara Therapeutics reports six-month response rate in bladder cancer trial - Investing.com
Protara Therapeutics reports six-month response rate in bladder cancer trial By Investing.com - Investing.com South Africa
Protara reports 68.0% six-month CR rate in 25 BCG-unresponsive patients, warrants exercisable through June 29, 2026 - TradingView
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics Inc Stock: Clinical Progress and Strategic Outlook for Investors in Tearnatin a - AD HOC NEWS
Profit Recap: Is Protara Therapeutics Inc still a buy after recent gains2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-03-26 17:09:27 - baoquankhu1.vn
Aug Swings: Can Protara Therapeutics Inc deliver consistent dividends2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Protara Therapeutics Inc stock faces volatility amid clinical pipeline updates and biotech sector pr - AD HOC NEWS
Form 144 Protara Therapeutics For: 6 March By Investing.com - Investing.com Australia
Aug Ideas: What is the Moat Score of Protara Therapeutics IncMarket Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Sentiment Recap: Whats the profit margin of Protara Therapeutics IncGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February - MarketBeat
Equities Analysts Offer Predictions for TARA Q1 Earnings - MarketBeat
Lifesci Capital Issues Optimistic Estimate for TARA Earnings - MarketBeat
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):